(Q51901729)

17 April 2018

meta-analysis

0 references

title

On the concept of remission in schizophrenia. (English)

1 reference

17 April 2018

0 references

3

Werner Kissling

1 reference

17 April 2018

Stefan Leucht

series ordinal

1

object named as

Stefan Leucht

1 reference

17 April 2018

author name string

Romain Beitinger

series ordinal

2

1 reference

17 April 2018

publication date

6 July 2007

1 reference

17 April 2018

published in

Psychopharmacology

1 reference

17 April 2018

volume

194

1 reference

17 April 2018

issue

4

1 reference

17 April 2018

page(s)

453-461

1 reference

17 April 2018

https://scigraph.springernature.com/pub.10.1007/s00213-007-0857-1

exact match

0 references

cites work

The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0857-1

Longitudinal studies of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0857-1

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0857-1

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0857-1

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0857-1

Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study

21 January 2018

1 reference

12 December 2020

Remission criteria for schizophrenia: evaluation in a large naturalistic cohort

1 reference

12 December 2020

Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study

1 reference

12 December 2020

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

12 December 2020

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

12 December 2020

A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia

1 reference

12 December 2020

Direct transition to long-acting risperidone--analysis of long-term efficacy

1 reference

12 December 2020

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

12 December 2020

Establishment of remission criteria for anxiety disorders.

1 reference

12 December 2020

The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials.

1 reference

12 December 2020

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

1 reference

12 December 2020

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

1 reference

12 December 2020

Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection

1 reference

12 December 2020

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

12 December 2020

Patient-based and clinician-based support for the remission criteria in schizophrenia.

1 reference

12 December 2020

What does the PANSS mean?

1 reference

12 December 2020

Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders

1 reference

12 December 2020

Validation of remission criteria for schizophrenia.

1 reference

12 December 2020

Remission in schizophrenia: proposed criteria and rationale for consensus

1 reference

12 December 2020

Clinical implications of Brief Psychiatric Rating Scale scores

1 reference

12 December 2020

Linking the PANSS, BPRS, and CGI: clinical implications

1 reference

12 December 2020

Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.

1 reference

12 December 2020

The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia

1 reference

12 December 2020

Recovery from psychotic illness: a 15- and 25-year international follow-up study

1 reference

12 December 2020

Remission and cognitive ability in a cohort of patients with schizophrenia.

1 reference

12 December 2020

Dropout rates in randomised antipsychotic drug trials

1 reference

12 December 2020

Assessment of remission in schizophrenia with the CGI and CGI-SCH scales

1 reference

12 December 2020

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group

1 reference

12 December 2020

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

12 December 2020

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

12 December 2020

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

1 reference

12 December 2020

Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group

1 reference

12 December 2020

The concepts of remission and recovery in schizophrenia

1 reference

12 December 2020

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

Treatment of negative symptoms in schizophrenia with amisulpride

1 reference

12 December 2020

One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

1 reference

12 December 2020

Standardized remission criteria in schizophrenia.

1 reference

12 December 2020

10.1007/S00213-007-0857-1

Identifiers

DOI

1 reference

17 April 2018

1 reference

17 April 2018